Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy

Journal of Rheumatology

Volumn 26, Issue 6, 1999, Pages 1347-1351

  McComb, Jennifer ^a   Gould, Ty ^a   Chlipala, Elizabeth ^a   Sennelo, Gina ^a   Frazier, Jan ^a   Kieft, Gary ^a   Seely, James ^a   Edwards III, Carl K ^a   Bendele, Alison ^a  

^a AMGEN INC   (United States)

Author keywords

Adjuvant arthritis; Soluble TNF receptor; Tumor necrosis factor

Indexed keywords

MACROGOL; TUMOR NECROSIS FACTOR RECEPTOR;

ADJUVANT ARTHRITIS; ANIMAL MODEL; ANKLE; ARTICLE; BONE EROSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; HEPATOMEGALY; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; MALE; NONHUMAN; OSTEOLYSIS; PAW EDEMA; PRIORITY JOURNAL; RAT; SPLENOMEGALY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIGENS, CD; AREA UNDER CURVE; ARTHRITIS, EXPERIMENTAL; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; INFLAMMATION; MALE; ORGAN SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED LEW; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TARSUS, ANIMAL; TREATMENT OUTCOME;

EID: 0033067522     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
2. Van de Loo FAJ, Joosten LAB, van Lent PLEM. Role of interleukin-1, tumor necrosis factor-a and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of initial blocking in murine antigen and zymosan induced arthritis. Arthritis Rheum 1995;38:164-72.
3. Khale P, Saal JG, Schaudt K. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992;51:731-4.
4. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, N Engl J Med 1997;337:141-7.
5. Moreland LW, Margolies G, Heck J, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein, toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
6. Elliot MJ, Maini RN, Feldman M, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
7. Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956;91:95-100.
8. Carlson RP, Datko LJ, O'Neil-Davis L, et al. Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred wistar rats. Int J Immunopharmacol 1985;7:811-26.
9. Benslay DN, Bendele AM. Development of a rapid screen for detecting and differentiating immunomodulatory vs antiinflammatory compounds in rats. Agents Actions 1991; 34:254-6.
10. Edwards CK III, Henry G, Seely J. et al. A phase I/II study to evaluate the safety, immunogenicity, pharmacokinetics and potential efficacy of human tumor necrosis factor binding protein PEGylated dimer (TNFbp) in patients with active rheumatoid arthritis [abstract]. Cell Mol Biol 1998a; Supp 404:38.
11. Edwards CK III, Frazier J, Seely J, et al. Assessment of the major antigenic epitopes of the recombinant human soluble p55 TNF type 1 receptor: design of a novel monomeric non-immunogenic analog. sTNF.RI (abstract). Arthritis Rheum 1998;41: Suppl 58:153.
12. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Pallidino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen arthritis in mice. Proc Natl Acad Sci USA 1992;89:7375-9.
13. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
14. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-4.
15. Wooley PH, Dulcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
16. Issekutz AC, Meager A, Otterness I, Issekutz TB. The role of tumor necrosis factor alpha and IL-1 in polymorphonuclear leukocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 1994;97:26-32.
17. Mori L, Iselin S, de Libero GD, Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-deficient mice, J Immunol 1996;157:3178-82.
18. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. Arthritis Rheum 1996;39:797-809.